Treating Multiple Myeloma Patients With Oral Therapies

Clinical Lymphoma, Myeloma and Leukemia

Volumn 17, Issue 5, 2017, Pages 243-251

  Kumar, Shaji K ^a   Vij, Ravi ^b   Noga, Stephen J ^c   Berg, Deborah ^c   Brent, Lonnie ^c   Dollar, Lawrence ^c   Chari, Ajai ^d  

^a MAYO CLINIC   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Adverse events; Efficacy; Management; Quality of life

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; IXAZOMIB; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DIARRHEA; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; LONG TERM CARE; LUNG EMBOLISM; MEDICATION COMPLIANCE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PATIENT AUTONOMY; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA;

EID: 85017166580     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2017.02.024     Document Type: Review

References (54)

1. 1 Palumbo, A., Anderson, K., Multiple myeloma. N Engl J Med 364 (2011), 1046–1060.
2. 2 Dimopoulos, M.A., Richardson, P.G., Moreau, P., Anderson, K.C., Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 12 (2015), 42–54.
3. 3 Kumar, S.K., Dispenzieri, A., Lacy, M.Q., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28 (2014), 1122–1128.
4. 4 Benboubker, L., Dimopoulos, M.A., Dispenzieri, A., et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371 (2014), 906–917.
5. 5 Palumbo, A., Hajek, R., Delforge, M., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366 (2012), 1759–1769.
6. 6 Palumbo, A., Gay, F., Cavallo, F., et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol 33 (2015), 3459–3466.
7. 7 Zafar, S.Y., Financial toxicity of cancer care: it's time to intervene. J Natl Cancer Inst, 108, 2016, 10.1093/jnci/djv370.
8. 8 Baz, R., Lin, H.M., Hui, A.M., et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer 23 (2015), 2789–2797.
9. 9 Romanus, D., Raju, A., Yong, C., Duration of therapy in US patients treated for relapsed/refractory multiple myeloma (RRMM) in the real-world. Haematologica, 538, 2016 abstract E1301.
10. 10 Richardson, P.G., Palumbo, A., Mateos, M.-V., van de Velde, H., Skacel, T., Lonial, S., The current unmet medical needs in the treatment and management of multiple myeloma. Clin Lymphoma Myeloma Leuk, 15, 2015, e244.
11. 11 Chen, C., Reece, D.E., Siegel, D., et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 146 (2009), 164–170.
12. 12 Dimopoulos, M., Spencer, A., Attal, M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007), 2123–2132.
13. 13 Dimopoulos, M.A., Swern, A.S., Li, J.S., et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J, 4, 2014, e257.
14. 14 San Miguel, J., Weisel, K., Moreau, P., et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14 (2013), 1055–1066.
15. 15 Baz, R.C., Martin, T.G. 3rd, Lin, H.Y., et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 127 (2016), 2561–2568.
16. 16 Palumbo, A., Bringhen, S., Caravita, T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006), 825–831.
17. 17 Palumbo, A., Falco, P., Corradini, P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 25 (2007), 4459–4465.
18. 18 Richardson, P.G., Siegel, D.S., Vij, R., et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 123 (2014), 1826–1832.
19. 19 Dimopoulos, M.A., Palumbo, A., Corradini, P., et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 128 (2016), 497–503.
20. 20 Magarotto, V., Bringhen, S., Offidani, M., et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 127 (2016), 1102–1108.
21. 21 Durie, B., Hoering, A., Rajkumar, S.V., et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG s0777. Blood, 126, 2015 abstract 25.
22. 22 Moreau, P., Masszi, T., Grzasko, N., et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374 (2016), 1621–1634.
23. 23 Richardson, P.G., Weller, E., Lonial, S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116 (2010), 679–686.
24. 24 Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 (2015), 142–152.
25. 25 Takeda Pharmaceuticals Limited. NINLARO® (ixazomib) capsules, for oral use. Prescribing information. Available at: https://www.ninlarohcp.com/prescribing-information.pdf, 2015 Accessed: December 20, 2016.
26. 26 Novartis. FARYDAK® (panobinostat) capsules, for oral use. Prescribing information. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/farydak.pdf, 2016 Accessed: December 20, 2016.
27. 27 Chari, A., Cho, H.J., Leng, X., et al. A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood, 126, 2015 abstract 4226.
28. 28 Dimopoulos, M., Oriol, A., Nahi, H., et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 (2016), 1319–1331.
29. 29 Lonial, S., Dimopoulos, M., Palumbo, A., et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 (2015), 621–631.
30. 30 HematologyAmgen NRCOi. Kyprolis summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003790/WC500197694.pdf, 2015 Accessed: December 20, 2016.
31. 31 Weber, D.M., Chen, C., Niesvizky, R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007), 2133–2142.
32. 32 GlaxoSmithKline. ALKERAN® (melphalan) capsules, for oral use. Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf, 2011 Accessed: December 20, 2016.
33. 33 Celgene. REVLIMID® (lenalidomide) capsules, for oral use. Prescribing information. Available at: http://www.revlimid.com/wp-content/uploads/full-prescribing-information.pdf, 2015 Accessed: December 20, 2016.
34. 34 Celgene. POMALYST® (pomalidomide) capsules, for oral use. Prescribing information. Available at: http://www.pomalyst.com/wp-content/uploads/prescribing_information.pdf, 2015 Accessed: December 20, 2016.
35. 35 Celgene. THALOMID® (thalidomide) capsules, for oral use. Prescribing information. Available at: http://www.celgene.com/content/uploads/thalomid-pi.pdf, 2015 Accessed: December 20, 2016.
36. 36 Baxter Healthcare. Cyclophosphamide tablets for oral use. Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090, 012142s112lbl.pdf, 2013 Accessed: December 20, 2016.
37. 37 Leleu, X., Terpos, E., Sanz, R.G., et al. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). Am J Hematol 91 (2016), 806–811.
38. 38 Reece, D., Kouroukis, C.T., Leblanc, R., Sebag, M., Song, K., Ashkenas, J., Practical approaches to the use of lenalidomide in multiple myeloma: a Canadian consensus. Adv Hematol, 2012, 2012, 621958.
39. 39 Tremblay, D., Choudhury, N., Ravikumar, A., Levine, A.C., Chari, A., The characterization of adrenal insufficiency and identification of its risk factors in patients with plasma cell dyscrasias. Am J Hematol 90 (2015), E202–E203.
40. 40 Merk & Co. I. DECADRON® (Dexamethasone Tablets, USP). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf, 2004 Accessed: December 20, 2016.
41. 41 Pawlyn, C., Khan, M.S., Muls, A., et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood 124 (2014), 2467–2468.
42. 42 Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 (2008), 414–423.
43. 43 Barley, K., He, W., Agarwal, S., Jagannath, S., Chari, A., Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma 57 (2016), 2510–2515.
44. 44 Kumar, S.K., Bensinger, W.I., Zimmerman, T.M., et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 124 (2014), 1047–1055.
45. 45 Baxter Healthcare. SPC cyclophosphamide tablets 50 mg. Available at: https://www.medicines.org.uk/emc/medicine/30161, 2016 Accessed: December 20, 2016.
46. 46 Baxter Healthcare. SPC dexamethasone tablets. Available at: https://www.medicines.org.uk/emc/medicine/28919, 2016 Accessed: December 20, 2016.
47. 47 Simchowitz, B., Shiman, L., Spencer, J., et al. Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs 14 (2010), 447–453.
48. 48 Center for Health Transformation. The 21st Century Intelligent Pharmacy Project: the importance of medication adherence. 2010. Available at: http://adhereforhealth.org/wp-content/uploads/pdf/The21stCenturyIntelligentPharmacyProject_MedicationAdherence_Mirixa_2010.pdf.
49. 49 Kurtin, S., Colson, K., Tariman, J.D., Finley-Oliver, E., Adherence, persistence, and treatment fatigue in multiple myeloma. J Adv Pract Oncol, 7, 2016, 7.
50. 50 Arber, A., Odelius, A., Williams, P., Lemanska, A., Faithfull, S., Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study. Eur J Cancer Care (Engl), 26, 2017.
51. 51 Hartigan, K., Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 7 (2003), 21–24.
52. 52 Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., Van Hecke, A., Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39 (2013), 610–621.
53. 53 Ramsey, S.D., Bansal, A., Fedorenko, C.R., et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34 (2016), 980–986.
54. 54 Cook, R., Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm 14 (2008), 19–25.